This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Able and willing to sign the informed consent (IC)
Patients with a diagnosis of AD and onset of disease for at least 1 year
Moderate to severe AD
Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
Participant with any other active inflammatory skin disease
Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)